When is the next results date for Gland Pharma?

No Upcoming Board Meetings

Has Gland Pharma declared dividend?

Yes, Gland Pharma has declared a dividend of 2000% (₹20 per share) with an ex-date of August 16, 2024. While the dividend yield is 1.23%, total returns have varied, showing negative performance in the short term but a strong positive return of 76.32% over the last two years.

Gland Pharma Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 2000%<BR>- Amount per share: 20 per share<BR>- Ex-date: 16 Aug 24<BR><BR>Dividend Yield: 1.23%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -9.24%, the dividend return was 0%, resulting in a total return of -9.24%.<BR><BR>Over the past year, the price return was -10.71%, with a dividend return of 1.06%, leading to a total return of -9.65%.<BR><BR>For the 2-year period, the price return was 74.37%, the dividend return was 1.95%, resulting in a total return of 76.32%.<BR><BR>In the last 3 years, the price return was -42.39%, the dividend return was 0.77%, leading to a total return of -41.62%.<BR><BR>Over the past 4 years, the price return was -47.67%, with a dividend return of 0.62%, resulting in a total return of -47.05%.<BR><BR>In the last 5 years, the price return was 0%, the dividend return was 0%, leading to a total return of 0.0%.<BR><BR>Overall, Gland Pharma has declared a significant dividend, but the total returns over various periods show a mixed performance, with negative returns in the shorter terms and a strong positive return over the 2-year period.

Who are the peers of the Gland Pharma?

Gland Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, J B Chemicals, Pfizer, Emcure Pharma, and Wockhardt. Gland Pharma has a good management risk rating but shows below-average growth and a 1-year return of -11.87%, significantly lower than Wockhardt's 174.76%.

Peers: Gland Pharma's peers include Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, J B Chemicals &, Pfizer, Emcure Pharma, and Wockhardt.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and the rest. Good management risk is found at Divi's Lab., Torrent Pharma, Gland Pharma, J B Chemicals &, Pfizer, Emcure Pharma, and Wockhardt. Below Average growth is noted at Divi's Lab., Torrent Pharma, Gland Pharma, Pfizer, and Emcure Pharma, while Excellent growth is seen at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs. Average growth is present at J B Chemicals &, and the rest. Excellent capital structure is held by Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Gland Pharma, J B Chemicals &, Pfizer, while Good capital structure is noted at Torrent Pharma and Emcure Pharma, and Below Average capital structure is found at Wockhardt.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Wockhardt at 174.76%, while Gland Pharma has the lowest at -11.87%. Gland Pharma's return is significantly lower than the highest peer. Additionally, the six-month return is negative for Gland Pharma, Emcure Pharma, and Wockhardt.

Who are in the management team of Gland Pharma?

As of March 2023, Gland Pharma's management team includes Chairman Yiu Kwan Stanley Lau, Managing Director & CEO Srinivas Sadu, and several non-executive and independent directors, totaling nine key members.

As of March 2023, the management team of Gland Pharma includes the following individuals:<BR><BR>1. Yiu Kwan Stanley Lau - Chairman & Independent Director<BR>2. Srinivas Sadu - Managing Director & CEO<BR>3. Qiyu Chen - Non-Executive & Non-Independent Director<BR>4. Udo Johannes Vetter - Non-Executive & Non-Independent Director<BR>5. C S N Murthy - Independent Director<BR>6. Essaji Goolam Vahanvati - Independent Director<BR>7. Naina Lal Kidwai - Independent Director<BR>8. Jia Ai (Allen) Zhang - Non-Executive & Non-Independent Director<BR>9. Yao Fang - Non-Executive & Non-Independent Director<BR><BR>This team comprises a mix of executive and non-executive directors, with several independent directors contributing to the governance of the company.

What does Gland Pharma do?

Gland Pharma Ltd is a large-cap pharmaceutical company, incorporated in 1978, with net sales of ₹14,249 Cr and a net profit of ₹1,865 Cr for the quarter ending March 2025. It has a market cap of ₹31,575 Cr and key metrics include a P/E ratio of 46.00 and a dividend yield of 1.05%.

Overview:<BR>Gland Pharma Ltd is a large-cap company operating in the Pharmaceuticals & Biotechnology industry.<BR><BR>History:<BR>Gland Pharma Limited was incorporated as 'Gland Pharma Private Limited' on March 20, 1978, and later renamed to 'Gland Pharma Limited' with a fresh certificate of incorporation issued on April 25, 1995. The most recent quarterly results report net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 14,249 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 1,865 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: INR 31,575 Cr (Large Cap)<BR><BR>Key Metrics:<BR>- P/E: 46.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 1.05%<BR>- Debt Equity: -0.25<BR>- Return on Equity: 7.63%<BR>- Price to Book: 3.41<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are the top shareholders of the Gland Pharma?

The top shareholders of Gland Pharma include Fosun Pharma Industrial Pte. Ltd. with 51.83%, mutual funds with 31.16%, and foreign institutional investors holding 6.9%. The largest public shareholder is Mirae Asset Large & Midcap Fund at 6.78%, while individual investors own 2.99%.

The top shareholders of Gland Pharma include Fosun Pharma Industrial Pte. Ltd, which holds the largest stake at 51.83%. Additionally, mutual funds collectively hold 31.16% of the shares, with 24 different schemes involved. Among foreign institutional investors (FIIs), there are 163 holding 6.9% of the company. The highest public shareholder is Mirae Asset Large & Midcap Fund, which owns 6.78%. Individual investors account for 2.99% of the holdings.

How big is Gland Pharma?

As of 24th July, Gland Pharma Ltd has a market capitalization of 32,804.00 Cr, with recent net sales of 5,616.50 Cr and a net profit of 698.52 Cr.

As of 24th July, Gland Pharma Ltd has a market capitalization of 32,804.00 Cr, categorizing it as a Large Cap company.<BR><BR>In the latest four quarters, Gland Pharma reported Net Sales of 5,616.50 Cr and a Net Profit of 698.52 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 8,723.84 Cr and Total Assets of 10,610.81 Cr.

Are Gland Pharma latest results good or bad?

Gland Pharma's latest results show a year-on-year net profit growth of 12.32%, but a sequential decline in profitability and operating margins raises concerns about its performance amidst increasing margin pressures. Overall, the results are mixed, highlighting both positive growth and significant challenges.

Gland Pharma's latest results present a mixed picture. On one hand, the company reported a net profit of ₹183.68 crore for Q2 FY26, which reflects a year-on-year growth of 12.32%. This indicates some resilience in profitability compared to the same quarter last year. However, the sequential performance shows a concerning decline of 14.76% from the previous quarter, alongside a slight decrease in net sales by 1.24%.<BR><BR>The operating margin also saw significant compression, dropping to 21.11% from 24.43% in the prior quarter, which is a decline of 332 basis points. This margin pressure, coupled with an increase in the effective tax rate from 31.10% to 35.30%, has further impacted the bottom line.<BR><BR>While the year-on-year growth in net profit and sales is a positive sign, the sequential declines in both profitability and margins suggest that Gland Pharma is facing challenges in its operating environment. Overall, the results indicate that while there are some positive aspects, the recent performance raises concerns about the company's ability to maintain its profitability amidst margin pressures.

Is Gland Pharma overvalued or undervalued?

As of November 7, 2025, Gland Pharma is considered overvalued with a PE ratio of 38.88, an EV to EBITDA of 4.16, and a PEG ratio of 2.72, indicating it is more expensive compared to peers like Sun Pharma and Cipla, and has underperformed the Sensex recently.

As of 7 November 2025, Gland Pharma's valuation grade has moved from very expensive to expensive, indicating a shift in perception regarding its market worth. The company is currently considered overvalued. Key ratios include a PE ratio of 38.88, an EV to EBITDA of 4.16, and a Price to Book Value of 0.32, which suggest that while the company has a low book value relative to its market price, its earnings multiples are high compared to peers.<BR><BR>In comparison to its industry peers, Gland Pharma's PE ratio is higher than Sun Pharma's 35.17 and significantly higher than Cipla's attractive PE of 22.33. Additionally, the PEG ratio of 2.72 indicates that the stock may not be growing fast enough to justify its current price. Recent stock performance shows that Gland Pharma has underperformed the Sensex over the past week and month, which further supports the view that it is overvalued in the current market context.

How has been the historical performance of Gland Pharma?

Gland Pharma's historical performance shows fluctuating financial metrics, with net sales of 5,616.50 Cr in March 2025, a decrease from the previous year but an increase from March 2023. Profitability declined, with profit after tax falling to 698.53 Cr, while total assets and liabilities increased to 11,172.85 Cr.

Answer:<BR>The historical performance of Gland Pharma shows a fluctuating trend in key financial metrics over the past several years.<BR><BR>Breakdown:<BR>Gland Pharma's net sales reached 5,616.50 Cr in March 2025, a slight decrease from 5,664.72 Cr in March 2024, but a significant increase from 3,624.60 Cr in March 2023. The total operating income mirrored this trend, with 5,616.50 Cr in March 2025 compared to 5,664.72 Cr in the previous year. Total expenditure, excluding depreciation, was 4,347.58 Cr in March 2025, showing a marginal increase from 4,331.65 Cr in March 2024. Operating profit (PBDIT) for March 2025 was 1,482.53 Cr, down from 1,503.31 Cr in March 2024, while profit before tax was 1,062.66 Cr, a decrease from 1,132.54 Cr in the prior year. Profit after tax also fell to 698.53 Cr in March 2025 from 772.46 Cr in March 2024. The company's total assets increased to 11,172.85 Cr in March 2025 from 10,610.81 Cr in March 2024, and total liabilities rose to 11,172.85 Cr from 10,610.81 Cr in the same period. Cash flow from operating activities was 914.00 Cr in March 2025, down from 996.00 Cr in March 2024, while net cash inflow for March 2025 was 2,199.00 Cr, a recovery from a net outflow of 1,551.00 Cr in March 2024. Overall, Gland Pharma's financial performance reflects both growth and challenges in profitability and cash flow management over the years.

Should I buy, sell or hold Gland Pharma?

Is Gland Pharma technically bullish or bearish?

As of December 1, 2025, the market trend is neutral with mixed signals, showing a shift from mildly bearish to sideways, as indicators like the weekly MACD and Bollinger Bands remain bearish while the monthly KST is bullish, but overall indecision is evident due to weak RSI and OBV readings.

As of 1 December 2025, the technical trend has changed from mildly bearish to sideways. The current technical stance is neutral, with mixed signals across different indicators. The weekly MACD and Bollinger Bands are both mildly bearish, while the monthly KST shows bullishness. Daily moving averages indicate a mildly bullish trend, but overall, the lack of strong signals from the RSI and OBV suggests indecision in the market. The stock has underperformed against the Sensex over multiple time frames, indicating weakness.

Which are the latest news on Gland Pharma?

Why is Gland Pharma falling/rising?

As of 03-Dec, Gland Pharma Ltd's stock price is rising to 1,771.70, reflecting a 0.23% increase. This upward trend follows two days of gains and is supported by a significant rise in investor participation, despite longer-term challenges.

As of 03-Dec, Gland Pharma Ltd's stock price is rising, currently at 1,771.70, reflecting a change of 4.1 (0.23%) upward. This increase follows a trend of consecutive gains over the last two days, during which the stock has risen by 2.64%. Additionally, the stock reached an intraday high of Rs 1814.15, marking a 2.63% increase at that point.<BR><BR>Investor participation has also seen a significant rise, with delivery volume on 02 Dec increasing by 155.21% compared to the 5-day average. This heightened activity suggests growing interest and confidence among investors. Furthermore, the stock's performance today is described as inline with the sector, indicating that it is not underperforming relative to its peers.<BR><BR>Despite some longer-term challenges, such as a decline of 10.16% over the past month and a 19.50% drop over the last five years, the current upward movement can be attributed to recent positive trading activity and increased investor engagement. The company's low debt-to-equity ratio and high institutional holdings at 40.54% may also contribute to a more stable outlook, as institutional investors typically have more resources to analyze the company's fundamentals.